GW Pharmaceuticals begins new study; a phase two clinical trial
People living with schizophrenia, whose current medication is not fully effective, will participate in a new study to see if CBD is safe and effective when used alongside an anti-psychotic drug, according to a newly registered clinical trial.
The research builds on the findings of a phase one study that showed lower levels of psychotic symptoms in participants who took the drug combo.
“CBD had beneficial effects in patients with schizophrenia.”
The first study, published in the American Journal of Psychiatry, suggested that: “CBD had beneficial effects in patients with schizophrenia.”
It said that CBD “may represent a new class of treatment for the disorder.”
The phase two study is expected to include approximately 366 patients in the randomized, double blind trial.
The clinical trial is in the “recruiting patients” phase and expected to have completed results in June 2022.
